[DOI] [PubMed] [Google Scholar] 68.Jastreboff A.M., Aronne L.J., Ahmad N.N., Wharton S., Connery L., Alves B., Kiyosue A., Zhang S., Liu B., Bunck M.C., Stefanski A
These growing patient populations are creating substantial demand for therapies that offer both glycemic control and weight reduction benefits
Pioneering studies from the past few years have demonstrated that aggregate clinical data, real-world data (such as data on pharmacovigilance or from electronic health records) and multi-omics data are alternative tools well suited to investigating the underlying mechanisms and clinical presentations of irAEs
Dehydration represents the primary kidney-related risk with GLP-1 use, because these medications slow stomach emptying and often reduce hunger-driven fluid intake
Semaglutide can cause slight heart-rate changes and, rarely, palpitations in early treatment phases, though most effects resolve as the body adjusts